H
Huajun Zhang
Researcher at Chinese Academy of Sciences
Publications - 50
Citations - 6061
Huajun Zhang is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Medicine & Virus. The author has an hindex of 17, co-authored 33 publications receiving 4794 citations. Previous affiliations of Huajun Zhang include Guangzhou Institutes of Biomedicine and Health & Australian Animal Health Laboratory.
Papers
More filters
Journal ArticleDOI
Bats are natural reservoirs of SARS-like coronaviruses.
Wendong Li,Zhengli Shi,Meng Yu,Wuze Ren,Craig Smith,Jonathan H. Epstein,Hanzhong Wang,Gary Crameri,Zhihong Hu,Huajun Zhang,Jianhong Zhang,Jennifer A. McEachern,Hume Field,Peter Daszak,Bryan T. Eaton,Shuyi Zhang,Lin-Fa Wang +16 more
TL;DR: It is reported that species of bats are a natural host of coronaviruses closely related to those responsible for the SARS outbreak, and these viruses display greater genetic variation than SARS-CoV isolated from humans or from civets.
Journal ArticleDOI
Effectiveness of convalescent plasma therapy in severe COVID-19 patients.
Kai Duan,Bende Liu,Li Cesheng,Huajun Zhang,Ting Yu,Jieming Qu,Min Zhou,Li Chen,Shengli Meng,Hu Yong,Cheng Peng,Mingchao Yuan,Jinyan Huang,Zejun Wang,Jianhong Yu,Xiaoxiao Gao,Dan Wang,Xiaoqi Yu,Li Li,Jiayou Zhang,Xiao Wu,Bei Li,Yanping Xu,Wei Chen,Peng Yan,Yeqin Hu,Lin Lianzhen,Xuefei Liu,Shihe Huang,Zhou Zhijun,Lianghao Zhang,Yue Wang,Zhang Zhi,Kun Deng,Zhiwu Xia,Gong Qin,Wei Zhang,Xiaobei Zheng,Ying Liu,Huichuan Yang,Dongbo Zhou,Ding Yu,Jifeng Hou,Zhengli Shi,Sai-Juan Chen,Zhu Chen,Xinxin Zhang,Xiaoming Yang +47 more
TL;DR: CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases and the optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.
Journal ArticleDOI
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Shengli Xia,Kai Duan,Yuntao Zhang,Dongyang Zhao,Huajun Zhang,Zhiqiang Xie,Xinguo Li,Cheng Peng,Yan-Bo Zhang,Wei Zhang,Yunkai Yang,Wei Chen,Xiaoxiao Gao,Wangyang You,Xue-Wei Wang,Zejun Wang,Zhengli Shi,Y. Wang,Xuqin Yang,Lianghao Zhang,Lili Huang,Qian Wang,Jia Lu,Yongli Yang,Jing Guo,Wei Zhou,Xin Wan,Cong Wu,Wenhui Wang,Shihe Huang,Du Jianhui,Ziyan Meng,An Pan,Zhiming Yuan,Shuo Shen,Wanshen Guo,Xiaoming Yang +36 more
TL;DR: In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing.
Journal ArticleDOI
A serological survey of SARS-CoV-2 in cat in Wuhan.
Qiang Zhang,Huajun Zhang,Jindong Gao,Kun Huang,Yong Yang,Xianfeng Hui,Xinglin He,Chengfei Li,Wenxiao Gong,Yufei Zhang,Ya Zhao,Cheng Peng,Xiaoxiao Gao,Huanchun Chen,Zhong Zou,Zhengli Shi,Meilin Jin +16 more
TL;DR: It is demonstrated that SARS-CoV-2 has infected cats in Wuhan during the outbreak and serum antibody dynamics in cats are described, providing an important reference for clinical treatment and prevention of COVID-19.
Journal ArticleDOI
Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques.
Chao Shan,Yanfeng Yao,Xing-Lou Yang,Yiwu Zhou,Ge Gao,Yun Peng,Lian Yang,Xue Hu,Jin Xiong,Ren-Di Jiang,Huajun Zhang,Xiaoxiao Gao,Cheng Peng,Juan Min,Ying Chen,Hao-Rui Si,Jia Wu,Peng Zhou,Yan-Yi Wang,Hongping Wei,Wei Pang,Zheng-Fei Hu,Longbao Lv,Yong-Tang Zheng,Zhengli Shi,Zhiming Yuan +25 more
TL;DR: It is demonstrated that neutralizing antibodies generated from the primary infection could protect the Rhesus macaques from a second-round challenge by SARS-CoV-2, and the non-human primate model that is established here provides a valuable platform to study Sars-Co V-2 pathogenesis and to evaluate candidate vaccines and therapeutics.